DOI: 10.1515/mr-2023-0068
Clinical characteristics and pharmacokinetics of PAXLOVID in COVID-19 patients with hematological tumor
Wei Liu1
Ping Yang1
Li Yang2
Hongmei Jing1
Libo Zhao2
Rongsheng Zhao3
1.Department of Pharmacy,Peking University Third Hospital,Beijing,China;Therapeutic Drug Monitoring and Clinical Toxicology Center of Peking University,Beijing,China;Institute for Drug Evaluation,Peking University Health Science Center,Beijing,China;NMPA Key Laboratory for Research and Evaluation of Generic Drugs,Beijing,China2.Department of Hematology,Peking University Third Hospital,Beijing,China3.Department of Pharmacy,Peking University Third Hospital,Beijing 100191,China;Therapeutic Drug Monitoring and Clinical Toxicology Center of Peking University,Beijing 100191,China;Institute for Drug Evaluation,Peking University Health Science Center,Beijing,China;NMPA Key Laboratory for Research and Evaluation of Generic Drugs,Beijing 100191,China
摘要：To the editor:Since the onset of COVID-19,several new treatments have been studied,but only a few have received approval for clinical use.However,a challenge we still face is that in real-world medical practice,the patient population may differ from those in clinical trials.For instance,pro-longed viral elimination has become an issue in immuno-compromised patients[1,2].
机标关键词：characteristicscovid-19kineticsclinicaltumorwithhematologicalpatients
论文发表日期：2024-04-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：3( 169-171 )